By Professor Glenda Gray
As a young paediatrician working at a hospital in Soweto, on the outskirts of Johannesburg, I was confronted with an epidemic that would define the trajectory of my career. Children—many just days old—were battling HIV, a virus that had robbed them of the chance for a healthy childhood. At that time, there was no option to stand by and do nothing. We galvanized efforts to reduce vertical transmission of HIV through research and action. Armed with science, we worked tirelessly to make interventions accessible to pregnant women living with HIV.
Those efforts have paid off. Today, we witness the tangible impact of decades of work: a marked reduction in pediatric HIV. This progress is a testament to what can be achieved when determination meets innovation. However, it is not enough.
Our next challenge is within sight. We must eliminate HIV—and this is an endeavour we should pursue relentlessly. Over the past two decades, I, along with other scientists, have dedicated myself to this cause. The ultimate goal remains the development of an HIV vaccine—an essential tool that has the potential to prevent new infections in both children and adults. This vision calls for the best minds in HIV vaccine research to unite in pursuit of this global mission.
On the 21st of September 2023, the South African Medical Research Council (SAMRC) announced that the U.S. Agency for International Development (USAID) had awarded the BRILLIANT Consortium up to $45 million to implement the HIV Vaccine Innovation, Science, and Technology Acceleration in Africa (HIV-VISTA) programme. This initiative represents a monumental step forward in the quest for an HIV vaccine, combining world-class expertise, cutting-edge science, and a commitment to collaboration.
The BRILLIANT Consortium—an acronym for Bringing Innovation to Clinical and Laboratory research to end HIV/AIDS In Africa through New vaccine Technology —is far more than a funding recipient. It is a coalition of diverse partners united by a shared purpose. Together, we co-created a proposal that integrates rigorous scientific methodologies with deeply thoughtful community engagement.
The BRILLIANT Consortium is unique in several ways. First, it is led by African scientists, underscoring the importance of local leadership in addressing a challenge that disproportionately affects the continent. Africa bears the greatest burden of the global HIV epidemic, and it is fitting—and long overdue—that African expertise drives the solution.
Second, the consortium exemplifies the power of collaboration. By bringing together researchers, institutions, and organisations with complementary expertise, the BRILLIANT Consortium ensures that no stone is left unturned in the pursuit of a vaccine. This approach reflects the understanding that solving complex global health challenges requires diverse perspectives and skills.
Lastly, the consortium is grounded in a vision of equity. The BRILLIANT Consortium is not only about scientific discovery; it is about ensuring that the benefits of this work reach those who need them most. By prioritising accessibility, the consortium aims to create a future where no child—or adult—contracts HIV, regardless of where they live.
The road to an HIV vaccine is neither short nor easy. It demands relentless commitment, bold innovation, and unwavering hope. But history has shown us that progress is possible. Just as we have drastically reduced pediatric HIV through vertical transmission prevention, we can—and must—aspire to eliminate the virus entirely.
The BRILLIANT Consortium represents a beacon of hope. It is a call to action for scientists, policymakers, funders, and communities to rally behind the mission of an HIV-free generation. With the support of initiatives like HIV-VISTA and the dedication of countless individuals, we are closer than ever to realising this vision.
As I reflect on the journey from Soweto to the global stage of vaccine research, I am filled with gratitude for the countless individuals who have shared this path. Together, we have turned despair into determination, obstacles into opportunities, and challenges into achievements.
The quest for an HIV vaccine is not just a scientific endeavour; it is a moral imperative. It is about ensuring that everyone has the chance to live a life free from the shadow of HIV. With the BRILLIANT Consortium leading the charge, I believe we are poised to achieve what once seemed impossible.
It is said that the best way to predict the future is to create it. With the BRILLIANT Consortium, we are creating a future where HIV will possibly be no longer a global health threat.
Professor Gray is the Chief Scientific Officer at the SAMRC and the Program Director for the BRILLIANT Consortium
Disclaimer: This website is made possible with the support of the American people through the United States Agency for International Development (USAID).
The contents are the sole responsibility of the BRILLIANT consortium and do not necessarily reflect the views of USAID or the United States Government.